Keeping you up to date on recent developments in orthopedics, including: Researchers develop new biomaterial that helps bones heal faster; Obesity increases the risk of early hip fracture in postmenopausal women; Vitamin D regulates calcium in intestine differently than previously thought.
Combining metabolic intervention with T-cell immunotherapy is safe and resulted in improved efficacy in two mouse models of solid tumors, providing an alternative combination strategy for boosting solid tumor immunotherapy, according to a new study by scientists at China Pharmaceutical University.
Keeping you up to date on recent developments in oncology, including: New assay may aid in the use of proteases as diagnostic for a range of cancers; New vulnerability in ‘KL’ KRAS subtype; Ferropoptosis gains new credibility as cancer treatment.
An international study led by Nanyang Technological University in Singapore has designed and synthesized broad-spectrum antimicrobial polymers (AMPs) and demonstrated the safety and efficacy of two such agents against multidrug-resistant (MDR) bacteria in mouse models of sepsis.
Despite concerns to the contrary, none of the mutations currently documented in the SARS-CoV-2 virus appear to increase its transmissibility in humans, according to a new analysis of viral genomes from 46,723 people in 99 countries who contracted COVID-19.
BioWorld looks at translational medicine, including: Overfeeding slows down liver’s response to glucose changes; Oncolytic virus combines best of both immune worlds.
Keeping you up to date on recent developments in cardiology, including: Remote help to lower BP, control cholesterol; Improving screening for dual heart disease; Candidate shows promise in reducing heart failure.
LONDON – The Google artificial intelligence company Deepmind has developed an algorithm that can predict the 3D structure of a protein from its amino acid sequence, making it possible to solve the structures of proteins, such as G-protein coupled receptors (GPCRs), which are a mainstay of drug targeting but whose structure is challenging to determine with current methods.
Moderna has announced that the primary efficacy analysis of the phase III COVE study of mRNA-1273 conducted on 196 cases has confirmed the high efficacy observed at the first interim analysis (ClinicalTrials.gov Identifier NCT04470427).
RSS
